Total revenue for 2025 was $106.0 million, an increase of 39% compared to $76.3 million in 2024. Net loss for 2025 reduced by 34% to $81.1 million, compared to a net loss of $122.7 million in 2024. Secured a $250.0 million non-recourse royalty-backed note financing from Royalty Pharma, providing non-dilutive capital. Utilized $62.5 million for share repurchases as of March 2, 2026, under the current authorized $125.0 million share repurchase program. Supplemental Biologics License Application (sBLA) for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) is expected to be completed by partner Jazz in 1Q 2026 in the U.S., with a potential launch in 2H 2026. Eligible to earn up to $440.0 million in milestone payments related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and China. Reported $270.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025. Anticipated cash runway beyond 2028, combining existing cash, expected GEA milestone payments, and Royalty Pharma proceeds, assuming full execution of the share repurchase plan.